Thrombopoietin Level Predicts Response to Treatment With Eltrombopag and Romiplostim in Immune Thrombocytopenia

American Journal of Hematology - United States
doi 10.1002/ajh.25275
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

Relative Potency of the Thrombopoietin Receptor Agonists Eltrombopag, Avatrombopag and Romiplostim in a Patient With Chronic Immune Thrombocytopenia

British Journal of Haematology
Hematology
2018English

The Thrombopoietin Mimetics Eltrombopag and Romiplostim in the Treatment of Refractory Aplastic Anaemia

British Journal of Haematology
Hematology
2016English

Eltrombopag-Based Combination Treatment for Immune Thrombocytopenia

Therapeutic Advances in Hematology
Hematology
2018English

Romiplostim as Early Treatment of Immune Thrombocytopenia With Severe Immunodeficiency

Hematology Reports
Hematology
2012English

Eltrombopag: An Update on the Novel, Non-Peptide Thrombopoietin Receptor Agonist for the Treatment of Immune Thrombocytopenia

Annals of Hematology
MedicineHematology
2010English

Erratum To: Treatment of 5 Dogs With Immune-Mediated Thrombocytopenia Using Romiplostim

BMC Veterinary Research
MedicineVeterinary
2016English

Eltrombopag, a Thrombopoietin- Receptor Agonist in the Treatment of Adult Chronic Immune Thrombocytopenia: A Review of the Efficacy and Safety Profile

Therapeutic Advances in Hematology
Hematology
2012English

Response to Steroids Predicts Response to Rituximab in Pediatric Chronic Immune Thrombocytopenia

Pediatric Blood and Cancer
OncologyChild HealthHematologyPerinatologyMedicinePediatrics
2011English

Response to Steroids Predicts Response to Rituximab in Pediatric Chronic Immune Thrombocytopenia.

Blood
BiochemistryImmunologyCell BiologyHematology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy